Strategic partnerships Leverage ongoing collaborations with MD Anderson, USC Keck, Mass General Brigham, and National University of Singapore to co-develop or validate PRIMAB-Dx in AML, multiple myeloma, and other hematologic malignancies, creating joint value propositions for pharma and biotech customers.

Clinical deployment Position PRIMAB-Dx as a CLIA-enabled, revenue-generating biomarker platform that can be offered to pharma partners running BH3 mimetic and apoptosis-targeted trials, accelerating adoption through near-term clinical trial applicability.

Funding signals Capitalize on a history of non-dilutive funding and SBIR grants plus ongoing revenue to support early commercialization initiatives, reduce risk for potential customers, and enable co-funded studies with industry partners.

Expansion opportunities Explore expansion into additional oncology indications such as multiple myeloma while maintaining a pipeline cadence, using existing research networks to shorten sales cycles and broaden market reach.

Global reach Highlight international collaboration with NUS and potential to engage global pharma partners, enabling cross-border studies and access to diverse patient populations to strengthen diagnostic platform credibility.